TipRanks on MSN
CG Oncology Advances Bladder Cancer Therapy Development
CG Oncology, Inc. ( ($CGON) ) has released its Q3 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors.
New results from a multicenter clinical trial show that combining immunotherapy drugs nivolumab and ipilimumab significantly improves treatment response in patients with advanced and ...
Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.
MedPage Today on MSN
Not-So-'Sneaky' Cells; Exercise for Breast Cancer; More Uses for AI in Cancer
A supervised exercise program helped patients with advanced breast cancer live longer, according to a study presented at the ...
In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...
Dr Mark Kris discusses how a small 2015 study with just two nivolumab doses led to a wave of curative-intent trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback